The Chronic Lymphocytic Leukemia Channel is supported with funding from AstraZeneca (Diamond), Johnson & Johnson (Gold) and Lilly (Silver).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
GCLLSG 2016 | Overview of the CLL2-BIG trial of ibrutinib and obinutuzumab
Julia von Tresckow, MD of University of Cologne, Cologne, Germany, discusses the CLL2-BIG trial (NCT02345863), which is one of four trials with the triple-T concept of a tailored and targeted treatment aimed at total eradication of minimal residue disease (MRD). The CLL2-BIG trial is an exploratory Phase II trial designed to show that a combination regimen of ibrutinib and obinutuzumab is safe and efficacious in an all-comer population. Recorded at the 2016 International Workshop of the German CLL Study Group (GCLLSG) in Cologne, Germany.
